Inspire Medical Systems is in a sustained downtrend, with the stock price declining 62.8% over the past year. The current price of $51.76 sits at 35.2% of its 52-week range (low $38.91, high $147.03), indicating it is trading near the lower end of its range. This positioning suggests the stock is deeply oversold and potentially undervalued, but also reflects persistent selling pressure and a lack of bullish catalysts. The 52-week low of $38.91 provides a critical support level, while the high of $147.03 represents significant resistance. Short-term momentum shows a sharp divergence: the 1-month price change is +22.4%, while the 3-month change is -4.2% and the 1-year change is -62.8%. This recent bounce from the May lows (around $40) could signal a potential trend reversal or a temporary relief rally within a broader downtrend. The relative strength index (RSI) is not provided, but the volume spike in early July (e.g., 1.29 million shares on July 10) suggests increased buying interest. The stock's beta of 0.71 indicates it is less volatile than the market, meaning the decline is more company-specific than macro-driven. Key support is at the 52-week low of $38.91; a break below that could open the door to further downside. Resistance is at the 52-week high of $147.03, but near-term resistance is around $55-$60 (recent highs). A breakout above $55 would be a positive signal, while a breakdown below $40 would be bearish.

Inspire Medical Systems has demonstrated strong revenue growth, with the most recent quarterly revenue estimated at $1.199 billion (consensus), though specific quarterly figures are not provided. The company's revenue trajectory has been robust, driven by increasing adoption of the Inspire system in the U.S. and expansion into Europe and Asia. However, the growth rate may be decelerating as the market matures and competition emerges. The company is profitable, with a net margin of 15.9% and an operating margin of 5.6%. Gross margin is exceptionally high at 85.4%, typical for medical device companies with proprietary technology. Net income is positive, with EPS of $0.05 (trailing twelve months), indicating the company has achieved profitability. The balance sheet is strong: the current ratio is 6.08, indicating ample liquidity, and debt-to-equity is only 0.04, suggesting minimal leverage. Free cash flow is not explicitly provided, but the PCF ratio of 23.2 implies positive cash flow. ROE is 18.6%, reflecting efficient use of equity. The company generates enough cash to fund operations and growth internally, reducing dependence on external financing.